KalVista Pharmaceuticals, Inc.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals is dedicated to advancing science to empower everyday lives, with a primary focus on hereditary angioedema (HAE). Their mission is to change the treatment landscape by developing orally-delivered small molecule medicines to address unmet needs and improve the standard of care for patients with HAE and other diseases.

Products & Services

Oral On-demand Treatment for HAE:The first and only oral on-demand treatment option for hereditary angioedema (HAE), aimed at offering new possibilities for managing the disease.

Oral Factor XIIa Inhibitor:A product in development as part of their pipeline focused on innovative treatments for HAE and related conditions.

EKTERLY (sebetralstat):An oral on-demand treatment for hereditary angioedema, recently approved by the European Commission and Swissmedic.

Specialties

Hereditary Angioedema (HAE) treatments Orally-delivered small molecule medicines Innovative drug development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Senior Notes T: - FT: Convertible Senior Notes	A: 110000000 MR: - FA: $110.0 million FAN: 110000000	D: 2025-09-24 FD: 2025-09-24	-
2	RT: Convertible Debt T: - FT: Convertible Debt	A: 125000000 MR: - FA: 125.0 million FAN: 125000000	D: 2025-09-24 FD: 2025-09-24	-
3	RT: Equity Offering T: - FT: Equity Offering	A: 55000000 MR: - FA: $55 million FAN: 55000000	D: 2024-11-04 FD: 2024-11-04	1 investors
4	RT: Synthetic Royalty Financing T: - FT: Synthetic Royalty Financing	A: 179000000 MR: - FA: up to $179 million FAN: 179000000	D: 2024-11-04 FD: 2024-11-04	1 investors
5	RT: Public Offering T: - FT: Public Offering	A: 160100000 MR: - FA: 160.1 million FAN: 160100000	D: 2024-02-15 FD: 2024-02-15	5 investors

Convertible Senior Notes Latest

2025-09-24

$110.0M

Convertible Debt 2025-09-24

$125.0M

Equity Offering 2024-11-04

$55.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

W

William (Bill) Fairey

Board Member

B

Benjamin L. Palleiko

Chief Executive Officer and Director

B

Brian J. G. Pereira

President and Chief Executive Officer of Visterra, Inc.

L

Laurence Reid

Entrepreneur, Company Builder, and Biotech Executive

N

Nancy Stuart

Former Chief Operating Officer

P

Patrick Treanor

Chief Operating Officer

View 12 more team members with Pro

Unlock Full Team Directory

Recent News